| Literature DB >> 26832985 |
Qiang Liu1, Jian Ma1, Xue-Feng Wang1, Fei Xiao1, Li-Jia Li1, Jiao-Er Zhang1, Yue-Zhi Lin1, Cheng Du1, Xi-Jun He2, Xiaojun Wang3, Jian-Hua Zhou4.
Abstract
The live equine infectious anemia virus (EIAV) vaccine strain EIAVDLV121 was developed by in vitro attenuation of a virulent strain, EIAVLN40, in the 1970s, and it has been demonstrated to induce protective immunity under laboratory and natural EIAV infection conditions. The detailed biological features of this attenuated virus remain to be further investigated. Experimental inoculation with EIAVDLV121 did not result in clinical symptoms even with immunosuppressive treatment in our previous studies. Here, we further investigated whether the replication of the vaccine strain EIAVDLV121 in experimentally infected horses causes histopathological lesions to develop in the targeted organs. Both the lungs and the spleen have been demonstrated to support EIAV replication. By evaluating the gross macroscopic and histological changes, we found that EIAVDLV121 did not cause detectable histopathological lesions and that it replicated several hundred times more slowly than its parental virulent strain, EIAVLN40, in tissues. Immunochemical assays of these tissues indicated that the primary target cells of EIAVDLV121 were monocytes/macrophages, but that EIAVLN40 also infected alveolar epithelial cells and vascular endothelial cells. In addition, both of these viral strains promoted the up- and down-regulation of the expression of various cytokines and chemokines, implicating the potential involvement of these cellular factors in the pathological outcomes of EIAV infection and host immune responses. Taken together, these results demonstrate that the EIAV vaccine strain does not cause obvious histopathological lesions or clinical symptoms and that it induces a unique cytokine response profile. These features are considered essential for EIAVDLV121 to function as an effective live vaccine.Entities:
Keywords: Cytokine expression; Equine infectious anemia virus; Horses; Macrophages; Pathological lesions
Mesh:
Substances:
Year: 2016 PMID: 26832985 PMCID: PMC7112881 DOI: 10.1016/j.vetimm.2016.01.006
Source DB: PubMed Journal: Vet Immunol Immunopathol ISSN: 0165-2427 Impact factor: 2.046
Fig. 1Histopathological observation of lungs and spleens. Tissue sections from horses infected with EIAVDLV121 (A and B) or EIAVLN40 (C and D) and uninfected negative controls (E and F) were stained with hematoxylin and eosin (H&E). Arrowheads indicate alveolar wall thickening; and arrows indicate severe histological inflammation and the emergence of macrophages, cell degeneration and necrosis of the alveolar walls (C). Arrowheads indicate serious hyperemia in the red pulp; and arrows indicate necrotic zones of variable sizes that appeared in the white pulp (D). The magnification of the lung is 100× and that of the spleen is 100×.
Fig. 2Immunohistochemistry of lungs and spleens. Immunohistochemical assays of the EIAV p26 capsid protein in these tissues from horses infected with either EIAVDLV121 (A and B) or EIAVLN40 (C and D) or from uninfected horses (E and F) were performed using a p26 monoclonal antibody and a horseradish peroxidase-conjugated secondary antibody. The arrows show the positively stained macrophages. The solid and hollow arrowheads indicate positively stained vascular endothelial cells and alveolar epithelial cells, respectively. The magnification is 50×.
Fig. 3Detection of EIAV RNA in peripheral blood mononuclear cells (PBMCs), lungs and spleens. Total RNA was extracted from these tissues. Levels of cell-associated EIAV RNA were quantitated by amplifying the gag gene fragment using real-time (RT)-PCR in tissue samples from animals infected with either EIAVDLV121 (A) or EIAVLN40 (B). Three samples from each lung and spleen were measured. *, P < 0.05 and **, P < 0.01 compared with the corresponding sample between groups. #, P < 0.05 and ##, P < 0.01 compared with the different samples within the same group. The triangle, square and circle represent different animals, respectively. The results for PBMCs from each horse are expressed as the mean values and those for each tissue site are expressed as the means ± SD (n = 4).
Measurement of cytokine and chemokine mRNA expression levels in tissues by quantitative real-time PCR.
| mRNA | Fold change | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Spleen ( | Lung ( | Intra-group (lung versus spleen) | Inter-group (EIAVLN40 versus EIAVDLV121) | ||||||||
| EIAVLN40 | EIAVDLV121 | EIAVLN40 | EIAVDLV121 | EIAVLN40 | EIAVDLV121 | Lung | Lung | Spleen | Spleen | ||
| Cytokines | IL-1α | 16.9 ± 9.8 | 4.3 ± 2.2 | 7.5 ± 2.3 | 3.5 ± 0.9 | NS | NS | NS | NS | NS | NS |
| IL-1β | 14.8 ± 3.9 | 2.9 ± 0.6 | 33.2 ± 17.3 | 1.0 | NS | 0.008 | NS | NS | 0.003 | 0.009 | |
| IL-6 | 269.9 ± 90.5 | 2.9 ± 0.4 | 149.4 ± 64.7 | 2.9 ± 1.2 | NS | NS | 0.04 | 0.04 | 0.009 | 0.009 | |
| IL-10 | 25.7 ± 12.8 | 1.4 | 4.2 ± 1.0 | 1.3 | NS | NS | 0.014 | 0.019 | NS | NS | |
| IFN-α | 323.8 ± 228.0 | 2.6 ± 1.4 | 9.3 ± 2.9 | NS | NS | 0.009 | NS | NS | NS | ||
| IFN-β | 28.1 ± 13.2 | 4.0 ± 2.0 | 1325.0 ± 872.8 | 1.5 | NS | NS | NS | NS | NS | NS | |
| IFN-γ | 1.2 | 33.4 ± 7.7 | 14.2 ± 4.0 | 14.8 ± 4.0 | 0.002 | 0.04 | NS | 0.04 | 0.004 | <0.001 | |
| MX1 | 5.1 ± 1.0 | 4.8 ± 1.3 | 1.4 | 3.8 ± 0.9 | 0.003 | NS | 0.02 | 0.019 | NS | NS | |
| Chemokines | IL-8 | 535.6 ± 99.0 | 4.5 ± 1.3 | 318.7 ± 111.9 | 4.3 ± 2.2 | NS | NS | <0.001 | <0.001 | 0.01 | 0.01 |
| CXCL10 | 147.7 ± 95.2 | 4.3 ± 0.5 | 31.8 ± 13.0 | 3.3 ± 0.5 | NS | NS | 0.034 | 0.04 | NS | NS | |
| Anti-apoptotic chemokines | CXCL12 | 48.2 ± 37.8 | 1.4 | 2.3 ± 0.8 | NS | <0.001 | 0.013 | NS | NS | NS | |
| CCL21 | 17.0 ± 9.7 | 1.2 | 1.5 | NS | NS | NS | NS | NS | NS | ||
UI: uninfected.
NS: not significant.
The arithmetic mean of the fold change of the expression level target gene relative to that of uninfected animals, and data are the mean ± SEM.
Increased expression level of cytokines and chemokines with a fold change >2.
Unchanged expression level was defined as fold change <2. Underlined data: decreased expression level with a fold change >2.
Student's t-tests were used for all comparisons.
Fig. 4An example of correlation analyses between cytokine mRNA expression levels and viral RNA copy numbers in tissues from EIAVDLV121-infected horses. EIAV genomic RNA and IFN-α (A) and IL-10 (B) mRNA were quantified by RT-PCR, as described in Fig. 3. Spearman's correlation coefficients (statistically significant: 0.5 < r < 0.8) and P values (significant: P < 0.05, very significant: P < 0.01) are provided in each graph.
Correlations between relative mRNA expression levels of the cytokines in tissues during EIAV infection.
| Group | Gene-specific | Comparison | Pearson's |
|---|---|---|---|
| EIAVDLV121 | EIAV | IFN-α | 0.663 (0.003) |
| IL-10 | 0.508 (0.031) | ||
| IFN-α | EIAV | 0.663 (0.003) | |
| IL-10 | 0.521 (0.026) | ||
| IFN-β | CXCL12 | 0.495 (0.037) | |
| IFN-γ | CCL21 | 0.484 (0.042) | |
| IL-1α | IL-10 | 0.53 (0.024) | |
| MX1 | 0.623 (0.006) | ||
| IL-1β | CXCL12 | 0.765 (<0.001) | |
| IL10 | EIAV | 0.508 (0.031) | |
| IFN-α | 0.521 (0.026) | ||
| IL-1α | 0.53 (0.024) | ||
| MX1 | IL-1α | 0.623 (0.006) | |
| CXCL10 | CCL21 | 0.485 (0.041) | |
| CXCL12 | IFN-β | 0.495 (0.037) | |
| IL-1β | 0.765 (<0.001) | ||
| CCL21 | IFN-γ | 0.484 (0.042) | |
| CXCL10 | 0.485 (0.041) | ||
| EIAVLN40 | EIAV | IFN-β | −0.689(0.002) |
| IL-1β | −0.687(0.002) | ||
| IL6 | 0.66 (0.003) | ||
| IFN-α | MX1 | 0.501 (0.034) | |
| IFN-β | EIAV | −0.689(0.002) | |
| IL-1β | 0.993 (<0.001) | ||
| IFN-γ | MX1 | −0.486 (0.041) | |
| IL-1α | CCL21 | 0.881 (<0.001) | |
| IL-1β | EIAV | −0.687(0.002) | |
| IL6 | EIAV | 0.66 (0.003) | |
| MX1 | IFN-α | 0.501 (0.034) | |
| IFN-γ | −0.486 (0.041) | ||
| CCL21 | IL-1α | 0.881 (<0.001) | |
Only Pearson's correlations for which P < 0.05 are shown.